Identification of a small molecule that modulates platelet glycoprotein Ib-von Willebrand factor interaction

Journal of Biological Chemistry

Volumn 287, Issue 12, 2012, Pages 9461-9472

  Broos, Katleen ^a   Trekels, Mieke ^a   Jose, Rani Alphonsa ^a   Demeulemeester, Jonas ^a   Vandenbulcke, Aline ^a   Vandeputte, Nele ^a   Venken, Tom ^a   Egle, Brecht ^a   De Borggraeve, Wim M ^a   Deckmyn, Hans ^a   De Maeyer, Marc ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PARTNERS; CLINICAL DEVELOPMENT; COFACTORS; COMPLEX FORMATIONS; DOCKING SCORE; GLYCOPROTEIN (GP); HIGH THROUGHPUT; IN-SILICO; IN-VITRO; IN-VIVO; MOLECULAR DOCKING; PLATELET ADHESION; PLATELET AGGREGATION; PROTEIN-PROTEIN INTERACTIONS; RISTOCETIN; SATURATION TRANSFER DIFFERENCE NMR; SMALL MOLECULES; SMALL-MOLECULE BINDINGS; SPECIFIC ACTIVITY; THROMBUS FORMATION; VON WILLEBRAND FACTOR; WHOLE BLOOD;

BIOCHEMISTRY; CHEMICAL MODIFICATION; GLYCOPROTEINS; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLATELETS; PROTEINS;

MOLECULES;

ANTITHROMBOCYTIC AGENT; COLLAGEN; GLYCOPROTEIN IB; MONOCLONAL ANTIBODY; RISTOCETIN; VON WILLEBRAND FACTOR;

ARTICLE; BINDING SITE; CHEMICAL MODIFICATION; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; SATURATION TRANSFER DIFFERENCE NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SHEAR RATE; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION;

BINDING SITES; BLOOD PLATELETS; DRUG EVALUATION, PRECLINICAL; HUMANS; KINETICS; MOLECULAR STRUCTURE; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; VON WILLEBRAND FACTOR;

EID: 84858609719     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.311431     Document Type: Article

References (69)

1. Dumas, J. J., Kumar, R., McDonagh, T., Sullivan, F., Stahl, M. L., Somers, W. S., and Mosyak, L. (2004) Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibα complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J. Biol. Chem. 279, 23327-23334 (Pubitemid 38685642)
2. Firbas, C., Siller-Matula, J. M., and Jilma, B. (2010) Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev. Cardiovasc Ther. 8, 1689-1701
3. Vanhoorelbeke, K., Ulrichts, H., Van de Walle, G., Fontayne, A., and Deck- myn, H. (2007) Inhibition of platelet glycoprotein Ib and its antithrombotic potential. Curr. Pharm. Des. 13, 2684-2697 (Pubitemid 47430434)
4. Cauwenberghs, N., Meiring, M., Vauterin, S., van Wyk, V., Lamprecht, S., Roodt, J. P., Novák, L., Harsfalvi, J., Deckmyn, H., and Kotzé, H. F. (2000) Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler. Thromb. Vasc. Biol. 20, 1347-1353 (Pubitemid 30262938)
5. Wu, D., Meiring, M., Kotze, H. F., Deckmyn, H., and Cauwenberghs, N. (2002) Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler. Thromb. Vasc. Biol. 22, 323-328 (Pubitemid 34127047)
6. Fontayne, A., Meiring, M., Lamprecht, S., Roodt, J., Demarsin, E., Barbeaux, P., and Deckmyn, H. (2008) The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb. Haemost. 100, 670-677
7. Gilbert, J. C., DeFeo-Fraulini, T., Hutabarat, R. M., Horvath, C. J., Merlino, P. G., Marsh, H. N., Healy, J. M., Boufakhreddine, S., Holohan, T. V., and Schaub, R. G. (2007) First-in-human evaluation of anti-von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 116, 2678-2686 (Pubitemid 350291240)
8. Knöbl, P., Jilma, B., Gilbert, J. C., Hutabarat, R. M., Wagner, P. G., and Jilma-Stohlawetz, P. (2009) Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 49, 2181-2185
9. Mayr, F. B., Knöbl, P., Jilma, B., Siller-Matula, J. M., Wagner, P. G., Schaub, R. G., Gilbert, J. C., and Jilma-Stohlawetz, P. (2010) The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion 50, 1079-1087
10. Bartunek, J., Barbato, E., Holz, J. B., Vercruysse, K., Ulrichts, H., and Heyndrickx, G. (2008) ALX-0081 a novel anti-thrombotic: results of a singledose phase 1 study in healthy volunteers and further development in patients with stable angina undergoing PCI. Circulation 118, S656
11. Ulrichts, H., Silence, K., Schoolmeester, A., de Jaegere, P., Rossenu, S., Roodt, J., Priem, S., Lauwereys, M., Casteels, P., Van Bockstaele, F., Verschueren, K., Stanssens, P., Baumeister, J., and Holz, J. B. (2011) Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 118, 757-765
12. Jones, S., and Thornton, J. M. (1996) Principles of protein-protein interactions. Proc. Natl. Acad. Sci. U.S.A. 93, 13-20 (Pubitemid 26038096)
13. Lo Conte, L., Chothia, C., and Janin, J. (1999) The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285, 2177-2198 (Pubitemid 29078179)
14. Clackson, T., and Wells, J. A. (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267, 383-386
15. Keskin, O., Ma, B., and Nussinov, R. (2005) Hot regions in protein-protein interactions. The organization and contribution of structurally conserved hot spot residues. J. Mol. Biol. 345, 1281-1294 (Pubitemid 40092239)
16. Dudkina, A. S., and Lindsley, C. W. (2007) Small molecule protein-protein inhibitors for the p53-MDM2 interaction. Curr. Top. Med. Chem. 7, 952-960 (Pubitemid 47040522)
17. Vassilev, L. T. (2007) MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13, 23-31
18. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., and Liu, E. A. (2004) In vivo activation of the p53 pathway by small molecule antagonists of MDM2. Science 303, 844-848 (Pubitemid 38174664)
19. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., Joseph, M. K., Kitada, S., Korsmeyer, S. J., Kunzer, A. R., Letai, A., Li, C., Mitten, M. J., Nettesheim, D. G., Ng, S., Nimmer, P. M., O'Connor, J. M., Oleksijew, A., Petros, A. M., Reed, J. C., Shen, W., Tahir, S. K., Thompson, C. B., Tomaselli, K. J., Wang, B., Wendt, M. D., Zhang, H., Fesik, S. W., and Rosenberg, S. H. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 435, 677-681 (Pubitemid 40825512)
20. Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., Roberts, L., Tahir, S. K., Xiao, Y., Yang, X., Zhang, H., Fesik, S., Rosenberg, S. H., and Elmore, S. W. (2008) ABT-263. A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428
21. Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., De Maeyer, M., Chaltin, P., and Debyser, Z. (2010) Rational design of small molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol. 6, 442-448
22. Sperandio, O., Reynès, C. H., Camproux, A. C., and Villoutreix, B. O. (2010) Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov. Today 15, 220-229
23. Shimizu, A., Matsushita, T., Kondo, T., Inden, Y., Kojima, T., Saito, H., and Hirai, M. (2004) Identification of the amino acid residues of the platelet glycoprotein Ib (GPIb) essential for the von Willebrand factor binding by clustered charged-to-alanine scanning mutagenesis. J. Biol. Chem. 279, 16285-16294 (Pubitemid 38509323)
24. Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., and Bourne, P. E. (2000) The Protein Data Bank. Nucleic Acids Res. 28, 235-242 (Pubitemid 30047768)
25. Emsley, J., Cruz, M., Handin, R., and Liddington, R. (1998) Crystal structure of the von Willebrand factor A1 domain and implications for the binding of platelet glycoprotein Ib. J. Biol. Chem. 273, 10396-10401 (Pubitemid 28227648)
26. Fukuda, K., Doggett, T. A., Bankston, L. A., Cruz, M. A., Diacovo, T. G., and Liddington, R. C. (2002) Structural basis of von Willebrand factor activation by the snake toxin botrocetin. Structure 10, 943-950 (Pubitemid 34786739)
27. Celikel, R., Varughese, K. I., Madhusudan, Yoshioka, A., Ware, J., and Ruggeri, Z. M. (1998) Crystal structure of the von Willebrand factor A1 domain in complex with the function blocking NMC-4 Fab. Nat. Struct. Biol. 5, 189-194 (Pubitemid 28113749)
28. Celikel, R., Ruggeri, Z. M., and Varughese, K. I. (2000) von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule. Nat. Struct. Biol. 7, 881-884
29. Huizinga, E. G., Tsuji, S., Romijn, R. A., Schiphorst, M. E., de Groot, P. G., Sixma, J. J., and Gros, P. (2002) Structures of glycoprotein Ibα and its complex with von Willebrand factor A1 domain. Science 297, 1176-1179 (Pubitemid 36196734)
30. Maita, N., Nishio, K., Nishimoto, E., Matsui, T., Shikamoto, Y., Morita, T., Sadler, J. E., and Mizuno, H. (2003) Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin. Insight into glycoprotein Ibα binding mechanism induced by snake venom proteins. J. Biol. Chem. 278, 37777-37781 (Pubitemid 37175304)
31. Fukuda, K., Doggett, T., Laurenzi, I. J., Liddington, R. C., and Diacovo, T. G. (2005) The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat. Struct. Mol. Biol. 12, 152-159
32. Celikel, R., McClintock, R. A., Roberts, J. R., Mendolicchio, G. L., Ware, J., Varughese, K. I., and Ruggeri, Z. M. (2003) Modulation of α-thrombin function by distinct interactions with platelet glycoprotein Ibα. Science 301, 218-221 (Pubitemid 36858476)
33. Brady, G. P., Jr., and Stouten, P. F. (2000) Fast prediction and visualization of protein binding pockets with PASS. J. Comput. Aided Mol. Des. 14, 383-401
34. Pettit, F. K., Bare, E., Tsai, A., and Bowie, J. U. (2007) HotPatch. A statistical approach to finding biologically relevant features on protein surfaces. J. Mol. Biol. 369, 863-879 (Pubitemid 46709917)
35. Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., and Berendsen, H. J. (2005) GROMACS. Fast, flexible, and free. J. Comput. Chem. 26, 1701-1718
36. Jorgensen, W. L., Maxwell, D. S., and Tirado-Rives, J. (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J. Am. Chem. Soc. 118, 11225-11236 (Pubitemid 26399746)
37. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., and Klein, M. L. (1983) J. Chem. Phys. 79, 926-935
38. Berendsen, H. J., Postma, J. P., Vangunsteren, W. F., Dinola, A., and Haak, J. R. (1984) Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684-3690
39. Darden, T., York, D., and Pedersen, L. (1993) Particle mesh Ewald: an N·log(N) method for Ewald. J. Chem. Phys. 98, 10089-10092
40. Hess, B., Bekker, H., Berendsen, H. J., and Fraaije, J. G. (1997) LINCS: a linear constraint solver for molecular simulations. J. Comp. Chem. 18, 1463-1472 (Pubitemid 127637344)
41. Halgren, T. (1999) MMFF VI. MMFF94s option for energy minimization studies. J. Comp. Chem. 20, 720-729
42. Voet, A. (2010) Development of Small Molecule Protein-Protein Interaction Inhibitors Targeting the HIV-1 Integrase-LEDGF/p75 Complex, Ph.D. thesis, K. U. Leuven, Leuven, Belgium
43. Oprea, T. (2005) Cheminformatics in Drug Discovery (Mannhold, R., Kubinyi, H., and Folkers, G., eds) pp. 141-175, Wiley-VCH, Weinheim, Germany
44. Vanhoorelbeke, K., Cauwenberghs, N., Vauterin, S., Schlammadinger, A., Mazurier, C., and Deckmyn, H. (2000) A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb. Haemost. 83, 107-113 (Pubitemid 30045485)
45. Schumpp-Vonach, B., Kresbach, G., Schlaeger, E. J., and Steiner, B. (1995) Stable expression in Chinese hamster ovary cells of a homogeneous recombinant active fragment of human platelet glycoprotein Ibα. Cytotechnology 17, 133-141
46. Tornai, I., Arnout, J., Deckmyn, H., Peerlinck, K., and Vermylen, J. (1993) A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains. J. Clin. Invest. 91, 273-282 (Pubitemid 23037282)
47. Ulrichts, H., Harsfalvi, J., Bene, L., Matko, J., Vermylen, J., Ajzenberg, N., Baruch, D., Deckmyn, H., and Tornai, I. (2004) A monoclonal antibody directed against human von Willebrand factor induces type 2B-like alterations. J. Thromb. Haemost. 2, 1622-1628 (Pubitemid 40186180)
48. Ulrichts, H., Udvardy, M., Lenting, P. J., Pareyn, I., Vandeputte, N., Vanhoorelbeke, K., and Deckmyn, H. (2006) Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J. Biol. Chem. 281, 4699-4707 (Pubitemid 43847729)
49. Grethe, G., and Moock, T. (1990) Similarity searching in REACCS. A new tool for the synthetic chemist. J. Chem. Inf. Comput. Sci. 363, 511-520
50. Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., and Simmerling, C. (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65, 712-725 (Pubitemid 44583220)
51. Parrinello, M., and Rahman, A. (1981) Polymorphic transitions in single crystals: A new molecular dynamics method. J. Appl. Phys. 5, 7182-7190 (Pubitemid 12456820)
52. Bussi, G., Donadio, D., and Parrinello, M. (2007) Canonical sampling through velocity rescaling. J. Chem. Phys. 126, 014101
53. Onufriev, A., Bashford, D., and Case, D. A. (2004) Exploring protein native states and large scale conformational changes with a modified generalized born model. Proteins 55, 383-394 (Pubitemid 38437495)
54. Case, D. A., Cheatham, T. E., 3rd, Darden, T., Gohlke, H., Luo, R., Merz, K. M., Jr., Onufriev, A., Simmerling, C., Wang, B., and Woods, R. J. (2005) The Amber biomolecular simulation programs. J. Comput. Chem. 26, 1668-1688 (Pubitemid 43076180)
55. Honig, B., Sharp, K., and Yang, A. S. (1993) Macroscopic models of aqueous solutions: biological and chemical applications. J. Phys. Chem. 97, 1101-1109
56. Mayer, M., and Meyer, B. (2001) Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J. Am. Chem. Soc. 123, 6108-6117 (Pubitemid 32888480)
57. Mayer, M., and James, T. L. (2004) NMR-based characterization of phenothiazines as a RNA binding scaffold. J. Am. Chem. Soc. 126, 4453-4460 (Pubitemid 38453903)
58. Eldridge, M. D., Murray, C. W., Auton, T. R., Paolini, G. V., and Mee, R. P. (1997) Empirical scoring functions. I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des. 11, 425-445 (Pubitemid 127505895)
59. Jones, G., Willett, P., Glen, R. C., Leach, A. R., and Taylor, R. (1997) Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267, 727-748 (Pubitemid 27170693)
60. Mayer, M., and Meyer, B. (1999) Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem. Int. Ed. Engl. 38, 1784-1788 (Pubitemid 29290947)
61. De Meyer, S. F., Schwarz, T., Deckmyn, H., Denis, C. V., Nieswandt, B., Stoll, G., Vanhoorelbeke, K., and Kleinschnitz, C. (2010) Binding of von Willebrand factor to collagen and glycoprotein Ibα, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice. Brief report. Arterioscler. Thromb. Vasc. Biol. 30, 1949-1951
62. Benard, S. A., Smith, T. M., Cunningham, K., Jacob, J., DeSilva, T., Lin, L., Shaw, G. D., Kriz, R., and Kelleher, K. S. (2008) Identification of peptide antagonists to glycoprotein Ibα that selectively inhibit von Willebrand factor dependent platelet aggregation. Biochemistry 47, 4674-4682 (Pubitemid 351555488)
63. McEwan, P. A., Andrews, R. K., and Emsley, J. (2009) Glycoprotein Ibα inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism. Blood 114, 4883-4885
64. Munoz Cdel, C., Campbell, W., Constantinescu, I., and Gyongyossy-Issa, M. I. (2008) Rational design of antithrombotic peptides to target the von Willebrand factor (vWf)-GPIb integrin interaction. J. Mol. Model 14, 1191-1202
65. Jorgensen, W. L. (2004) The many roles of computation in drug discovery. Science 303, 1813-1818
66. Guido, R. V., Oliva, G., and Andricopulo, A. D. (2008) Virtual screening and its integration with modern drug design technologies. Curr. Med. Chem. 15, 37-46 (Pubitemid 351234626)
67. Tan, X., Calderon-Villalobos, L. I., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., and Zheng, N. (2007) Mechanism of auxin perception by the TIR1 ubiquitin ligase. Nature 446, 640-645 (Pubitemid 46606890)
68. She, J., Han, Z., Kim, T. W., Wang, J., Cheng, W., Chang, J., Shi, S., Wang, J., Yang, M., Wang, Z. Y., and Chai, J. (2011) Structural insight into brassinosteroid perception by BRI1. Nature 474, 472-476
69. Sheard, L. B., Tan, X., Mao, H., Withers, J., Ben-Nissan, G., Hinds, T. R., Kobayashi, Y., Hsu, F. F., Sharon, M., Browse, J., He, S. Y., Rizo, J., Howe, G. A., and Zheng, N. (2010) Jasmonate perception by inositol-phosphate- potentiated COI1-JAZ co-receptor. Nature 468, 400-405